Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
New Denmark Study (doh ...)
Conclusions- EPA was associated with lower risks of most types of ischemic stroke, apart from cardioembolism, while inconsistent findings were observed for total marine n-3 PUFA and DHA.
https://www.ncbi.nlm.nih.gov/pubmed/30602356
Cool! Thanks Chas
New EPA source
https://www.ncbi.nlm.nih.gov/pubmed/30588551
fda-might-greenlight-drug-prescribing-apps-for-chronic-ailments
https://www.bloomberg.com/news/articles/2019-01-03/trump-s-fda-might-greenlight-drug-prescribing-apps-for-chronic-ailments
Video on R-I from NEJM
https://www.nejm.org/do/10.1056/NEJMdo005434/full/
To Betsy McKay author of WSJ article on fish oil
https://www.dropbox.com/s/f9gwuyz0c5lafio/IMG_6642.JPG?dl=0
Congrats, well done
the most important Trials in Cardiology
7. Fish Oil Finally Wins
Until Deepak Bhatt, MD, from Harvard University presented the stunningly positive REDUCE-IT trial,[19] nearly 80 studies of fish oil supplementation had failed to show any benefit.[20]
But In REDUCE-IT, a high dose (4 g daily) of purified eicosapentaenoic acid used in patients with high triglyceride levels reduced a composite of major cardiac events by almost 5% in absolute terms. All components of the composite endpoint were significantly reduced. Also remarkable was that these patients were receiving statin therapy and had median low-density lipoprotein cholesterol levels of 74 to 76 mg/dL.
Three factors caused skepticism over REDUCE-IT: One was its outlier nature; another was the unknown mechanism of benefit; and the third was concerns about potential harm from the mineral oil placebo, which was associated with significantly higher levels of non-high-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and apolipoprotein B. My take is that the (purified) brand and dose of fish oil plus the selection of patients with high triglycerides were enough to explain the results. During an interview, Professor Jane Armitage from Oxford thought that REDUCE-IT would apply to about 30% of patients with high triglyceride levels. She reminded me of something doctors often forget: The best way to reduce one's triglyceride levels is with diet and exercise. Prescription-strength fish oil will likely be expensive. We will see how this influences uptake.
REDUCE-IT: Icosapent ethyl reduces ischemic events in high-risk patients
Cardiology Today, December 2018
https://www.healio.com/cardiology/chd-prevention/news/print/cardiology-today/%7B0976e6ec-2fd1-464f-a894-50566e28e199%7D/reduce-it-icosapent-ethyl-reduces-ischemic-events-in-high-risk-patients
Conclusion
474 The current study found that higher levels of self-reported EPA intake were associated with
475 lower traits scores of physical aggression, but not measures of callous, unemotional, or uncaring
476 traits in two adult samples derived from the community. Furthermore, whilst EPA intake did not
477 associate with electrophysiological indices of face processing (N170), higher levels of EPA
478 intake were associated with larger Stop-P300 responses to facial distress, an electrophysiological
479 index of motor extinction proficiency, with this relationship thought to mediate the negative
480 association between EPA intake and physical aggression. These findings are in line with a role of
481 EPA in executive control over behavior, as cued by affective stimuli; rather than the initial
24
482 encoding of the emotional content of the face. There appears to be great logistical and financial
483 value in pursuing the use of n-3 supplementation as a potential, internationally-robust, tool for
484 reducing physical aggression. As such, due to their notable implications for clinical and forensic
485 populations, as well as community-based cohorts more generally, results reported in this
486 investigation should be of interest to forensic psychologists and behavioral scientists alike, and
487 provide a strong basis for future replication using more statistically-robust, biological methods.
https://www.dropbox.com/s/p5hilz5hi05y7fl/EPA%20and%20physical%20aggression%20JPSP%20%28pre-print%29.pdf?dl=0
Not fond of Motley Fool but a decent summary nonetheless
Fun reading re invention by Dr Mason Preston ( Inventor) assigned to Amarin
The subject: EPA MOA
Titled
METHODS OF REDUCING OR PREVENTING OXIDATION OF SMALL DENSE LDL OR MEMBRANE POLYUN SATURATED FATTY ACIDS
I find this most interesting since it contains figures showing relative effects of EPA to other molecules and propose the MOA that led to R-I results
https://www.dropbox.com/s/l5mo7d7dwbmjtzz/WO2015195662A1%20long.pdf?dl=0
This invention was granted a patent in August of 2018 for application 15/312,113
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20170087111.PGNR.&OS=DN/20170087111&RS=DN/20170087111
Worth a few billion...... at least
Among the 10 most important medical breakthroughs of 2018
http://www.thisisinsider.com/important-medical-discoveries-of-the-year-2018-12
?Publication: Emergence of omega-3 fatty acids in biomedical research
?https://www.dropbox.com/s/8ukls9fv4xpggb8/1-s2.0-S0952327818302151-main.pdf?dl=0?
Vascepa MOA elucidated
https://www.tandfonline.com/doi/full/10.1080/00325481.2017.1385365
Warning about website idea
A company’s brand integrity is among a companies most valued assets. (See new European Websites as an example) Anything that dilutes, or confuses the brand to consumers will likely be seen as deriding the efforts to establish the Vascepa brand being created , paid for by Amarin
Example: All aspects of the logo, exact color size etc is under strict control and if you begin to rebrand Vascepa, using new logos / images you’re repositioning the product and you may be slapped with a cease and desist order.
To thread the needle without stepping on Amarin’s toes, the primary mission should have a scope larger than Vascepa brand, and materially different than Amarin
While well intended, you don’t have the right to reuse brand logos or marketing content as if it yours
There’s a way to do it, but you need to be mindful not to cross the line.
There are tons of examples of existing consumer health-focused newspaper columns / websites, magazines that cover health issues and discuss a variety of topics. As an example Google words metformin anti aging
Do you really need to fund / create a new DTC website dedicated to Vascepa? I don’t think so. EPADI was mindful of the proprietary brand issues and stayed on point by publishing factual science available at the time.
Perhaps instead; put effort into writing compelling Op-Eds, articles / videos that get published on existing websites that get seen by consumers.
Same “thought leadership” content can be tweeted, posted on social media and allow it to go viral
Prepping for Europe... these domains were redirecting to http://vascepa.com . Now the website is online in each country’s domain
http://www.vascepa.it (Italy)
http://www.vascepa.de (Germany)
http://www.vascepa.fr (France)
http://www.vascepa.ie (ireland)
?Resolvin E1 ( from EPA) attenuates murine psoriatic dermatitis.
?https://www.ncbi.nlm.nih.gov/pubmed/30089836?
Here’s an idea: draft an outline for investigational journalist to review and publish the controversy of FDAs decision to keep Vascepa out of hands of those at risk resulting in death, MI, Stroke
If nothing else it would expand the exposure as a safe efficacious Drug
Maybe 60 min would do a story
We all know the answer
FDA will say TG lowering doesn’t work, but the trial data says EPA does
A bit of a quandary, no?
Tasty, I agree
Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis.
https://www.ncbi.nlm.nih.gov/pubmed/29391271?fbclid=IwAR0f2zz6CW4FG0U-nnTeFPVL1HIFU7vlV2cgs6WqLxsWfU6554qBOaPcu84
You're welcome garynavarre - glad you find it useful
New (Vascepa) Book on Amazon
"The Essential Guide to Prescription Drugs Update on fish oil: REDUCE-IT validates Vascepa Kindle Edition"
Description:
Did you know that Vascepa, the prescription EPA-icosapent ethyl only fish oil was proven to decrease Major Cardiac Adverse Events (MACE) by 25 percent in the REDUCE-IT study? It’s true. Vascepa is the only product that only has EPA and those supplements in health food stores are actually combination products with DHA and EPA which DO NOT have the same Vascepa proven benefits.
Our new Essential Guide to Prescription Drugs update on fish oil, REDUCE-IT validates Vascepa gives you detailed information in over 45 categories such as key drug interactions, Vascepa and breast feeding and pregnancy, possible side effects and much much more. Pre-order it today and know that we will include breaking Vascepa news from the November 10th Heart Association meeting. Vascepa is a True Breakthrough for heart patients. Find out why today!
There’s hope for fish
https://link.springer.com/article/10.1007/s11033-018-4476-1
?Mechanism of heart disease from autoimmune disease discovered, thankfully Vascepa blocks it
https://lupusnewstoday.com/2018/12/03/mechanism-behind-autoimmune-disease-heart-disease-found/ ?
?
https://www.ncbi.nlm.nih.gov/pubmed/?term=eicosapentaenoic+acid%5BTitle%2FAbstract%5D+Interleukin-17 $AMRN ?
Newsletter from Cardiologists
https://www.dropbox.com/s/02axo2hpu6l8maf/Heartbeat-Newsletter-November-2018.pdf?dl=0
HD - is your thesis of 50% swag coming from the use of larger, multi-product salesforce, larger advertising spend? and legitimacy and endorsement by a major pharma company, hence persuading more docs?
AVII, I agree , 1st Amendment right is for Doctors only.
Although the latest TV commercial comes close, it avoids making specific claims on R-I outcomes - which I find ridiculous - but that’s the FDA we’ve all come to know
EPA shown to gave favorable effects on skeletal muscle and whole-body energy metabolism.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0208048#abstract0
the never-ending therapeutic power of EPA ... attenuates House Dust Mite (HDM) -induced asthmatic inflammation
http://erj.ersjournals.com/content/52/suppl_62/PA1111 $AMRN
Preston Mason PhD elucidated how EPA + Statin together accelerate inhibition of oxidized LDL-C hence <plaque, fewer events. Here is Euro “combo" patent for EPA + atorvastatin - you think anyone might be interested in IP owned by AMRN that combines Lipitor +Vascepa into one drug?
Of course, that only doubles revenue potential.
https://www.dropbox.com/s/2ymjh2bsp0uc4a0/PHARMACEUTICAL%20COMPOSITION%20COMPRISING%20OMEGA-3%20FATTY%20ACID%20AND%20HYDROXY-DERIVATIVE%20OF%20A%20STATIN%20AND%20METHODS%20OF%20USING%20SAME.pdf?dl=0
FYI, Preston Mason EPA Patent allowed ASugist 2018:
METHODS OF REDUCING OR PREVENTING OXIDATION OF SMALL DENSE LDL OR MEMBRANE POLYUNSATURATED FATTY ACIDS
https://www.dropbox.com/s/2waxawghgm1tdab/15312113%20METHODS%20OF%20REDUCING%20OR%20PREVENTING%20OXIDATION%20OF%20SMALL%20DENSE%20LDL%20OR%20MEMBRANE%20POLYUNSATURATED%20FATTY%20ACIDS.pdf?dl=0